ThermoGenesis Holdings (THMO) Soars 31%

July 06, 2022 at 11:22 pm - by Editor Investors Prism

ThermoGenesis Holdings (THMO) shot up 31% for the day, despite not releasing any news.

ThermoGenesis works in the gene therapy field and develops and commercializes automated cell processing technologies.

THMO is currently a penny stock, sitting at $0.30 and a market cap slightly below $4M.

THMO is also housed in the PRISM MedDiagnostics Index, which is up 1.7% for the day, leading all PRISM indexes.

About ThermoGenesis Holdings, Inc.
ThermoGenesis Holdings, Inc. develops, commercializes, and markets a range of automated technologies for CAR-T and other cell-based therapies. The Company currently markets a full suite of solutions for automated clinical biobanking, point-of-care applications, and automation for immuno-oncology, including its semi-automated, functionally closed CAR-TXpress™ platform, which streamlines the manufacturing process for the emerging CAR-T immunotherapy market. For more information about ThermoGenesis, please visit: www.thermogenesis.com.